Thera-SAbDab

SIRUKUMAB

>   Structural Summary
TherapeuticSirukumab
TargetIL6
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2011
INN Year Recommended2012
Companies InvolvedCentocor Inc, GlaxoSmithKline, Janssen Biotech
Conditions Approvedna
Conditions ActiveGiant cell arteritis, Asthma, Lupus nephritis, Major depressive disorder
Conditions DiscontinuedRheumatoid arthritis, Atherosclerosis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]